Abstract
Chronic
respiratory
diseases
impose
a
substantial
health
burden
globally
with
increasing
prevalence
and
mortality
rates,
especially
in
affluent
nations.
Recent
studies
underscore
the
escalating
contribution
to
premature
morbidity
mortality,
highlighting
critical
need
for
effective
interventions.
Inflammatory
lung
diseases,
such
as
asthma,
chronic
obstructive
pulmonary
disease
(COPD),
acute
distress
syndrome
(ARDS),
idiopathic
fibrosis
(IPF),
have
significant
roles
this
that
are
characterized
by
heightened
inflammation
affecting
airways
or
parenchyma,
leading
restrictive
diseases.
These
conditions
often
exhibit
components,
which
complicate
classification
management.
Current
treatments
illnesses
predominantly
rely
on
systemic
drug
delivery,
may
result
poor
efficacy
adverse
effects
other
organs.
Inhalation
delivery
presents
promising
alternative,
offering
advantages,
targeted
deposition,
reduced
side
effects,
rapid
onset
of
action.
Despite
these
benefits,
inhalation
systems
still
developmental
stage,
particularly
local
delivery.
Dry
powder
inhalers
(DPIs)
emerged
popular
choice
due
ease
use,
high-dose
capability,
breath-activated
mechanisms.
This
review
delves
into
intriguing
world
spotlight
DPIs.
From
fascinating
design
principles
potential
precision
medicine,
DPIs
offer
glimpse
future
care.
By
unravelling
mysteries
DPI
formulation
performance
assessment,
aimed
propel
field
forward,
ushering
new
era
personalized
efficacious
therapies
inflammatory
beyond.
Furthermore,
article
delved
identification
prevalent
technologies
within
domain
while
also
probing
prospective
avenues
emerging
development.
Such
insights
aim
assist
researchers
making
informed
decisions
regarding
relevant
research
development
pursuits.
Polymers,
Год журнала:
2023,
Номер
15(18), С. 3849 - 3849
Опубликована: Сен. 21, 2023
The
evolution
of
respiratory
diseases
represents
a
considerable
public
health
challenge,
as
they
are
among
the
leading
causes
death
worldwide.
In
this
sense,
in
addition
to
high
prevalence
such
asthma,
chronic
obstructive
pulmonary
disease,
pneumonia,
cystic
fibrosis,
and
lung
cancer,
emerging
diseases,
particularly
those
caused
by
members
coronavirus
family,
have
contributed
significant
number
deaths
on
global
scale
over
last
two
decades.
Therefore,
several
studies
been
conducted
optimize
efficacy
treatments
against
these
focusing
drug
delivery
using
nanomedicine.
Thus,
development
nanocarriers
has
emerged
promising
alternative
overcome
limitations
conventional
therapy,
increasing
bioavailability
at
target
site
reducing
unwanted
side
effects.
context,
nanoparticles
composed
chitosan
(CS)
show
advantages
other
because
possesses
intrinsic
biological
properties,
anti-inflammatory,
antimicrobial,
mucoadhesive
capacity.
Moreover,
CS
potential
enhance
stability,
prolong
duration
action,
improve
targeting,
control
release,
dissolution
poorly
soluble
drugs,
increase
cell
membrane
permeability
hydrophobic
drugs.
These
properties
could
performance
after
its
administration.
review
aims
discuss
for
delivery,
highlighting
how
their
can
treatment
including
synergistic
action
with
encapsulated
drug.
Pharmaceutics,
Год журнала:
2024,
Номер
16(5), С. 680 - 680
Опубликована: Май 17, 2024
Lung
diseases
have
received
great
attention
in
the
past
years
because
they
contribute
approximately
one-third
of
total
global
mortality.
Pulmonary
drug
delivery
is
regarded
as
one
most
appealing
routes
to
treat
lung
diseases.
It
addresses
numerous
drawbacks
linked
traditional
dosage
forms.
presents
notable
features,
such
as,
for
example,
a
non-invasive
route,
localized
delivery,
low
enzymatic
activity,
degradation,
higher
patient
compliance,
and
avoiding
first-pass
metabolism.
Therefore,
pulmonary
route
commonly
explored
delivering
drugs
both
locally
systemically.
Inhalable
nanocarrier
powders,
especially,
lipid
nanoparticle
formulations,
including
solid-lipid
nanostructured-lipid
nanocarriers,
are
attracting
considerable
interest
addressing
respiratory
thanks
their
significant
advantages,
deep
deposition,
biocompatibility,
biodegradability,
mucoadhesion,
controlled
released.
Spray
drying
scalable,
fast,
commercially
viable
technique
produce
nanolipid
powders.
This
review
highlights
ideal
criteria
inhalable
spray-dried
SLN
NLC
powders
administration
route.
Additionally,
promising
inhalation
devices,
known
dry
powder
inhalers
(DPIs)
powder-based
medications,
applications
treating
chronic
conditions,
considered.
Journal of Advanced Research,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 1, 2025
Acute
lung
injury
(ALI)
is
a
life-threatening
condition
characterized
by
rapidly
progressing
respiratory
distress
and
hypoxemia.
Oxidative
stress-induced
inflammation
in
tissue
plays
crucial
role
the
progression
of
ALI.
Excessive
generation
reactive
oxygen
species
(ROS)
pulmonary
microenvironment
activates
inflammatory
signaling
pathways,
enhancing
transcription
pro-inflammatory
factors
ultimately
leading
to
necrosis.
Bilirubin
(BR),
an
exceptional
endogenous
antioxidant,
possesses
ability
counteract
elevated
levels
through
direct
reactions
or
inducing
antioxidant
systems
such
as
Nrf2/HO-1
signaling.
However,
its
limited
solubility
poses
hindrance
further
applications.
Hence,
it
imperative
develop
suitable
bilirubin-based
system
for
biological
utilization.
In
this
study,
we
developed
ROS-sensitive
adaptive
nanoscavenger
(GP@BR)
co-assembling
bilirubin-conjugated
glycol
chitosan
(GC-BR)
polyethylene
(PEG-BR),
aiming
alleviate
oxidative
stress
ALI
treatment.
The
different
conjugations
endowed
bilirubin
derivatives
with
varying
sensitivity
towards
reacting
ROS,
enabling
GP@BR
exert
antioxidative
properties
specifically
environments
on
demand.
Besides
excellent
properties,
also
demonstrated
absorb
excess
cytokines.
Moreover,
our
optimized
facilitated
transport
across
mucosal
layer
epithelial
cells.
vivo
studies
confirmed
that
significantly
improved
symptoms
suppressed
fibrosis.
This
study
highlighted
potential
multiple
actions
treatment
Current Pharmaceutical Design,
Год журнала:
2024,
Номер
31(4), С. 244 - 260
Опубликована: Апрель 30, 2024
In
recent
years,
advancements
in
chemistry
have
allowed
the
tailoring
of
materials
at
nanoscopic
level
as
needed.
There
are
mainly
four
main
types
nanomaterials
used
drug
carriers:metal-based
nanomaterials,
organic
inorganic
and
polymer
nanomaterials.
The
a
carrier
showed
advantages
for
decreased
side
effects
with
higher
therapeutic
index.
stability
compounds
increased
by
encapsulation
within
nano-drug
carriers,
leading
to
systemic
toxicity.
Nano-drug
carriers
also
controlled
release
system-made
solubility
characteristics
nanoparticles
surface
coating
surfactants.
review
focuses
on
different
nanoparticle
synthesis
process,
techniques
purposes,
applications
prospects
biomedical
applications.
Ferulic
acid
(FA),
a
phenolic
compound
abundant
in
the
cell
walls
of
seeds,
leaves,
and
roots
various
fruits,
vegetables,
cereals,
grains,
is
renowned
for
its
wide
range
biological
activities,
including
antioxidant,
anti-inflammatory,
antimicrobial,
anticancer
properties.
Despite
therapeutic
potential,
clinical
application
FA
hindered
by
challenges
such
as
poor
water
solubility,
limited
bioavailability,
rapid
metabolism,
instability
under
physiological
conditions.
To
address
these
issues,
nanotechnology
has
emerged
transformative
approach,
enhancing
FA's
pharmacokinetic
profile.
Various
nanoparticle-based
systems,
polymer-based
lipid-based
nanoparticles,
have
been
developed
to
encapsulate
FA.
These
systems
demonstrated
significant
improvements
stability,
with
studies
showing
enhanced
antioxidant
activity
controlled
release
profiles.
Further,
surface
engineering
nanoparticles
provides
targeted
drug/phytochemical
delivery
potential.
The
drugs/phytochemicals
significantly
enhances
efficacy
minimizes
systemic
side
effects.
This
review
explores
potential
FA,
limitations
application,
advancements
that
are
paving
way
effective
use.
European Journal of Pharmaceutics and Biopharmaceutics,
Год журнала:
2024,
Номер
204, С. 114530 - 114530
Опубликована: Окт. 10, 2024
Biological
products,
including
vaccines,
blood
components,
and
recombinant
therapeutic
proteins,
are
derived
from
natural
sources
such
as
humans,
animals,
or
microorganisms
typically
produced
using
advanced
biotechnological
methods.
The
success
of
biologics,
particularly
monoclonal
antibodies,
can
be
attributed
to
their
favorable
safety
profiles
target
specificity.
However,
large
molecular
size
presents
significant
challenges
in
drug
delivery,
overcoming
biological
barriers.
Pulmonary
delivery
has
emerged
a
promising
route
for
administering
offering
non-invasive
with
rapid
absorption,
high
systemic
bioavailability,
avoidance
first-pass
metabolism.
This
review
first
details
the
anatomy
physiological
barriers
respiratory
tract
associated
pulmonary
(PDD).
It
further
discusses
innovations
PDD,
impact
particle
on
deposition,
use
secondary
particles,
nanoparticles,
enhance
bioavailability
targeting.
also
explains
various
devices
used
dry
powder
inhalers
(DPIs)
nebulizers,
highlighting
advantages
limitations
delivering
biologics.
role
excipients
improving
stability
performance
inhalation
products
is
addressed.
Since
powders
considered
suitable
format
biomolecules,
particular
emphasis
placed
DPI
development.
final
section
article
reviews
compares
manufacturing
methods,
clarifying
clinical
relevance
potential
future
applications
field
inhalable
formulation.
